Source: China Economic Net
On August 26, Jiangsu Weikang Jiejing Medical Devices Co., Ltd. (hereinafter referred to as "Weikang Medical") will launch its first meeting. The sponsor is Soochow Securities Co., Ltd. They are Pan Zhesheng and Wang Maohua. Weikang Medical plans to list on the GEM of the Shenzhen Stock Exchange. It plans to issue no more than 15 million new shares, accounting for no less than 25% of the total share capital after the issuance. The company plans to raise funds of 368 million yuan, which will be used for the "new project of annual production of 11.5 million ultra-smooth antibacterial silicone catheters", "annual production of 48 million sputum suction tubes, 10 million of drainage bags and new projects" ", "Medical Polymer Materials R&D Center Construction Project", "Medical Device Marketing Network Project".
Weikang Medical has withdrawn its listing application twice. On September 25, 2017, Weikang Medical submitted an application for an initial public offering and listing on the main board of the Shanghai Stock Exchange, and subsequently withdrew the application; on June 18, 2019, Weikang Medical submitted an application for an initial public offering and started a business on the Shenzhen Stock Exchange Board listing application, the subsequent withdrawal of the application. The Shenzhen Stock Exchange asked the company why it had applied for an initial public offering twice and then withdrawn its application.
Before this issuance, the father and daughter of Liu Chunliang and Liu Lijie controlled 100% of the voting rights of the company through direct and indirect means, and were the actual controllers of the company; after this issuance, the proportion of voting rights controlled by Liu Chunliang and Liu Lijie was reduced to 75% %, still able to directly influence the issuer's major business decisions. In 2020 and 2021, the company's dividends and amounts are 100 million yuan, 50 million yuan, and 54 million yuan, respectively, with a total dividend of 204 million yuan. In 2022, the company passed a proposal to distribute a cash dividend of 13.5 million yuan to shareholders, which has not yet been implemented.
From 2018 to 2021, Weikang Medical achieved operating income of RMB 240.0452 million, RMB 261.9233 million, RMB 253.5520 million, and RMB 244.0974 million, of which the main business income was RMB 234.8748 million, RMB 254.3423 million, RMB 246.8555 million, and RMB 241.5975 million ten thousand yuan.
During the reporting period, the company’s net profits attributable to owners of the parent company were 68.8242 million yuan, 69.0439 million yuan, 54.705 million yuan, and 54.626 million yuan. 52.3023 million yuan, 58.0154 million yuan, 46.5551 million yuan, and 48.1898 million yuan.
During the reporting period, the net cash flow generated by the company's operating activities was 65.7728 million yuan, 79.8963 million yuan, 95.1564 million yuan, and 41.9541 million yuan, and the cash received from selling goods and providing labor services were 246.6148 million yuan and 270.0330 million yuan , 288,188,200 yuan, and 251,710,700 yuan.
From 2018 to 2021, the number of Weikang Medical employees will be 756, 700, 720 and 666 respectively.
From 2018 to 2021, Weikang Medical’s research and development expenses were 7.0837 million yuan, 7.9142 million yuan, 6.8119 million yuan, and 7.6052 million yuan. During the reporting period, the company's R&D expense ratios were 2.95%, 3.02%, 2.69%, and 3.12%, respectively, and the average R&D expense ratios of comparable companies in the same industry were 3.28%, 3.92%, 4.16%, and 4.50%. The company's R&D expense ratio in 2020 and 2021 is the lowest among comparable companies in the same industry. The overseas market of
mainly produces and sells in the form of OEM, that is, it produces according to the orders of overseas customers, and the products are sold after affixing the customer's trademark. During the reporting period, the company's overseas direct exports amounted to 111.745 million yuan, 135.2664 million yuan, 113.3438 million yuan and 106.3174 million yuan respectively, accounting for 47.58%, 53.18%, 45.92% and 44.01% of the main business income.
Weikang Medical disclosed in the prospectus that it was punished for three violations of laws and regulations during the reporting period. On October 26, 2018, the Jiangsu Provincial Drug Administration released on its official website the "National Medical Devices Supervision and Sampling Results Announcement (No. 7) (2018 No. 90) Disposal Situation in Jiangsu Province", to implement the behavior of Weikang Medical for the vacuum control device of the above-mentioned disposable sputum suction tube that does not meet the standards A fine of 20,000 yuan was imposed, and rectification measures were required to modify the mold and conduct verification.
On February 25, 2021, the Jiangsu Provincial Drug Administration issued the "Administrative Penalty Decision" to the company (Su Yao Jian Su Ji Pen [2020] 〕No. 9), because the company produced a disposable dressing change kit that did not meet the requirements of the registered product standard (the unqualified item was the residual amount of ethylene oxide ), a administrative penalty of 35,000 yuan was imposed .
2021 10 On March 12, the Jiangsu Provincial Drug Administration issued an "Administrative Penalty Decision" (Su Yao Jian Su Ji Pei [2021] No. 7) to Weikang Medical, because the company produced 300 disposable The ultraviolet absorbance of the nasogastric tube does not meet the requirements of the registered product standard (the value of the product is 7,425 yuan), and the company is given an administrative penalty of 45,000 yuan.
During the reporting period, the products sold by the company to some distributors were slow-moving or approaching the expiration date According to the agreement or the consensus of both parties, the company will return and exchange the relevant products. The amount of returned goods in each period during the reporting period was 580,200 yuan, 6,939,500 yuan, 1,976,900 yuan, and 319,000 yuan. During the reporting period, the company Returns due to unsalable and near-expiration dates accounted for a relatively high proportion of the corresponding shipments in previous years, most of which exceeded 5%.
In addition to the above-mentioned returns due to slow-moving and near-expiration dates, the company’s other main situations of returns and exchanges during the reporting period Returns and exchanges for products caused by packaging problems such as moisture or damage to the outer box due to logistics and transportation, quality problems in a few products, and wrong models placed by some customers. The return cycle is short, and most of them are within one month after delivery. occurred within.
is mainly engaged in disposable medical consumables and raised 368 million yuan. Father and daughter 100% hold
Weikang Medical’s main business is the research and development, production and sales of disposable medical consumables. After years of business development, the company’s products It has covered hundreds of specifications and models in the five series of surgical care, respiration, anesthesia, urology and puncture. The main products are suction tubes, sputum suction tubes, nasal oxygen tubes, drainage bags (including anti-reflux drainage bags, precision drainage bags), etc. Polymer material products.
As of the signing date of the prospectus, Hao Peng Industrial holds 77.27% of the company’s shares and is the controlling shareholder of the company. The actual controllers of the company are Liu Chunliang and Liu Lijie’s father and daughter. Among them: Liu Chunliang directly holds 13.64% of the company shares , Liu Chunliang and Liu Lijie indirectly control 77.27% of the company’s shares through Haopeng Industrial, and Liu Chunliang indirectly controls 9.09% of the company’s shares through Shanghai Hongjian. The number of new shares to be publicly issued shall not exceed 15 million, accounting for no less than 25% of the total share capital after issuance. The sponsor of this issuance is Soochow Securities Co., Ltd., and the sponsor representatives are Pan Zhesheng and Wang Maohua.
Weikang Medical plans to raise 368.2981 million yuan, of which 149.4019 million yuan will be used for the "new project with an annual output of 11.5 million ultra-smooth antibacterial silicone catheters", and 130.472 million yuan will be used for "annual production of 48 million sputum suction tubes, 1,000 Ten thousand drainage bags new project", 51.628 million yuan was used for the "medical polymer material research and development center construction project", and 36.7962 million yuan was used for the "medical device marketing network project".
Withdrew its listing application twice and was inquired
The Shenzhen Stock Exchange pointed out in the inquiry that on September 25, 2017, Weikang Medical submitted an application for an initial public offering and listing on the main board of the Shanghai Stock Exchange, and subsequently withdrew the application; on June 18, 2019 Riweikang Medical submitted an application for an initial public offering and listing on the Growth Enterprise Market of the Shenzhen Stock Exchange, but subsequently withdrew the application. The Shenzhen Stock Exchange asked the company why it had applied for an initial public offering twice and then withdrawn its application.
Regarding the first declaration, the company stated in the inquiry reply that in September 2017, Weikang Medical submitted an application for an initial public offering and listing on the main board of the Shanghai Stock Exchange, and withdrew the application in July 2018. The company's first declaration corresponds to the reporting period (2014-2017)The net profits attributable to the owners of the parent company after recurring gains and losses were 16.5318 million yuan, 39.6702 million yuan, 46.9214 million yuan and 50.5191 million yuan respectively. Considering the small scale of its own performance and the uncertainty of the main board audit, the company based on its own development Considering the strategy, the application is withdrawn and plans to apply for GEM separately.
This declaration was the company’s voluntary withdrawal of the application materials. The regulatory agency has not issued a standard rectification request to the company, and the withdrawal of the declaration has been completed for 36 months. Therefore, there are no matters that need to be rectified and implemented in this application or substantial obstacles affecting the issuance and listing.
Regarding the second declaration, the company stated that in June 2019, Weikang Medical submitted an application for an initial public offering and listing on the Growth Enterprise Market of the Shenzhen Stock Exchange. Withdraw the declaration application. Withdrawal of the application is mainly due to the company’s plan to adjust its business strategy, further focus on the main business of disposable medical consumables, and divest the land and real estate in Suzhou that have nothing to do with the production of its main business; the company expects that the review period will be significantly extended, facing the external Institutional investors are under pressure to cash in on returns; after the company's previous declaration period, some dealers had large-scale returns and exchanges, which involved retroactive adjustments to the financial statements in the previous declaration period.
The two-year dividend of 204 million yuan and 13.5 million yuan has not yet been implemented
On April 10, 2020, the company’s first extraordinary general meeting of shareholders in 2020 reviewed and approved the "Proposal on Profit Distribution Plan". Based on the total share capital of 55,000,000 shares at the end of 2019, the A cash dividend of 18.18 yuan (tax included) will be distributed for every 10 shares, and a total of 100 million yuan in cash dividends will be distributed to shareholders. The profit distribution plan will be implemented in June 2020.
On July 20, 2020, the company's 2019 annual general meeting of shareholders reviewed and approved the "Proposal on Profit Distribution Plan for 2019". Based on the total share capital of 55,000,000 shares at the end of 2019, a cash dividend of 9.09 yuan (tax included) will be distributed for every 10 shares. Shareholders distribute cash dividends of RMB 50 million. The profit distribution plan will be implemented in July 2020.
On June 18, 2021, the company's 2020 annual general meeting of shareholders reviewed and approved the "Proposal on Profit Distribution Plan for 2020". Based on the total share capital of 45,000,000 shares, cash of 12 yuan (including tax) will be distributed for every 10 shares, and the total cash will be distributed to shareholders Dividend of 54 million yuan. The profit distribution plan will be implemented in November 2021.
On May 10, 2022, the seventh meeting of the company's third board of directors reviewed and approved the "2021 Annual Profit Distribution Plan Proposal", based on the company's total share capital of 45,000,000 shares, a cash bonus of 3 yuan (tax included) will be distributed for every 10 shares , and distributed a total of 13.5 million yuan in cash dividends to shareholders. The profit distribution plan has been reviewed and approved by the 2021 annual general meeting of shareholders, but has not yet been implemented.
The performance has dropped for two consecutive years
The draft prospectus on September 30, 2021 shows that the net profit attributable to the issuer's shareholders after deducting non-recurring gains and losses in 2020 is 43.3281 million yuan. The relevant financial information of
as of June 30, 2022 has not been audited, but has been reviewed by Zhonghui accountants. According to the "Zhonghui Huiyue [2022] No. 6215" "Review Report" issued by Zhonghui Accountants, the company achieved operating income of 122.8547 million yuan from January to June 2022, an increase of 20.03% over the same period of the previous year; after deducting non-recurring gains and losses The net profit attributable to owners of the parent company was 31.7307 million yuan, an increase of 48.05% over the same period of the previous year.
The number of employees is on a downward trend
From 2018 to 2021, the number of employees of Weikang Medical will be 756, 700, 720, and 666, respectively.
From the perspective of professional structure, as of the end of the reporting period, the company had 469 production personnel, accounting for 70.42%.
From the perspective of education level, as of the end of the reporting period, the company had 531 employees with junior college or below, accounting for 79.73%.
Last year’s research and development expenses were 7.61 million yuan
2018By 2021, Weikang Medical's research and development expenses will be 7.0837 million yuan, 7.9142 million yuan, 6.8119 million yuan, and 7.6052 million yuan.
Among them, the amount of employee remuneration was 3.2253 million yuan, 3.3889 million yuan, 3.1727 million yuan, and 3.6753 million yuan, accounting for 45.53%, 42.82%, 46.58%, and 48.33% respectively.
During the reporting period, the company's R&D expense ratios were 2.95%, 3.02%, 2.69%, and 3.12%, respectively, and the average R&D expense ratios of comparable companies in the same industry were 3.28%, 3.92%, 4.16%, and 4.50%.
's R&D expense ratio in 2020 and 2021 is the lowest among comparable companies in the same industry. According to the prospectus of
, during the reporting period, the proportion of the company's R&D expenses to operating income was lower than the average value of comparable listed companies in the same industry, and there was a certain gap in the scale of R&D investment compared with comparable listed companies in the same industry, mainly due to: (1) During the reporting period , the company's research and development projects are mainly for the improvement of existing products and the automation of production lines, while comparable listed companies such as Kindly, Sanxin Medical, and Weili Medical have also improved interventional consumables and orthopedics on the basis of existing major product development and improvement. Consumables and other high-value medical consumables and medical equipment products such as blood purification devices have continued to invest in research and development, and the research and development aspects are more extensive; (2) The company's R&D personnel are mainly located in Shuyang , while the main business locations of Kindly and Weili Medical Located in economically developed regions such as Shanghai and Guangzhou, the average salary level of the company's R&D personnel is relatively low; (3) There is a certain gap between the company's investment in R&D facilities and comparable listed companies, and the depreciation costs of R&D facilities are relatively small.
Concentration of export customers
The sales market of Weikang Medical is mainly divided into overseas market and domestic market. The company combines its own development scale and product characteristics. The overseas market mainly produces and sells in the form of OEM, including direct export and indirect export; the domestic market mainly uses Distribution-based, supplemented by direct sales. The overseas market of
mainly produces and sells in the form of OEM, that is, it produces according to the orders of overseas customers, and the products are sold after affixing the customer's trademark. The company's overseas customers are mainly overseas large-scale medical device brand operators.
During the reporting period, the company's direct overseas exports amounted to 111.745 million yuan, 135.2664 million yuan, 113.3438 million yuan and 106.3174 million yuan respectively, accounting for 47.58%, 53.18%, 45.92% and 44.01% of the main business revenue. The main export customers of
are Cardinal, Medline, Intersurgical and HUM. The above four export customers are all well-known foreign medical device brand operators, and they accounted for more than 70% of the company's direct export revenue during the reporting period.
Three violations of laws and regulations received administrative penalties
Weikang Medical disclosed in the prospectus three violations of laws and regulations and punishments during the reporting period, including: the vacuum control device of the disposable sputum suction tube did not meet the standard requirements, and the one-time use replacement The residual amount of ethylene oxide in the drug pack was not up to the standard, and the ultraviolet absorbance of the disposable nasogastric tube was not up to the standard.
(1) Vacuum control device for disposable sputum suction tube does not meet the standard requirements
On September 20, 2018, China Food and Drug Administration issued the "Notice on the Results of National Medical Device Supervision and Sampling Inspection (No. 7) (2018 No. 90), the announcement shows that a batch of vacuum control devices for disposable sputum suction tubes produced by Weikang Medical did not meet the standards. On October 26, 2018, the Jiangsu Provincial Drug Administration issued the "Notice on the Results of the National Medical Device Supervision and Sampling Inspection (No. 7) (2018 No. 90) Disposal in Jiangsu Province" on its official website. If the vacuum control device of the one-time-use sputum suction tube does not meet the standards, a fine of 20,000 yuan will be imposed, and rectification measures such as modifying the mold and verifying it will be required. In November 2019, Shuyang County Market Supervision and Administration Bureau issued the "Administrative Punishment Decision" (Shushi Jian'anzi [2019] No. 10085) for the above-mentioned violations.
(2) The residual amount of ethylene oxide in the disposable dressing change kit does not meet the standard
On February 25, 2021, the Drug Administration of Jiangsu ProvinceThe regulatory bureau issued the "Administrative Penalty Decision" (Su Yaojian Su Jifei [2020] No. 9) to the company, because the company produced disposable dressing change kits that did not meet the requirements of the registered product standards (the unqualified item was ethylene oxide alkane residues), an administrative penalty of 35,000 yuan will be imposed. The above-mentioned one-time use dressing change kits that do not meet the requirements of the registered product standards are 2,000 packs, with a total value of 6,000 yuan. Considering that the company actively cooperated with the investigation after the incident, took effective measures to recall 818 packages of unqualified products and destroyed them, carefully investigated the reasons for the unqualified products, and took targeted measures for rectification, the Jiangsu Provincial Drug Administration imposed a moderate penalty.
(3) The UV absorbance of disposable nasogastric tubes does not meet the standard
Products are returned or exchanged due to unsalable, approaching the expiry date, or quality problems. The company will return and exchange related products as agreed or agreed upon by both parties.
The amounts returned in each period during the reporting period were 580,200 yuan, 6,939,500 yuan, 1,976,900 yuan, and 319,000 yuan.
During the reporting period, the company's returns due to slow sales and near-expiration dates accounted for a relatively high proportion of the corresponding shipments in previous years, mostly exceeding 5%.
Distributor customers involved are mainly distributors of Sinopharm, Suzhou Duojian Medical Instrument Co., Ltd. (hereinafter referred to as "Suzhou Duojian"), Foshan Jiejing Medical Instrument Co., Ltd. and its affiliated companies (the affiliated company is Foshan Yide Kang Medical Instrument Co., Ltd., hereinafter collectively referred to as "Foshan Jiejing").
In addition, in the 2020 distribution agreement signed by the company with five Sinopharm distributors including Hebei Sinopharm, Anhui Sinopharm, and Shandong Sinopharm, it is stipulated that if the varieties or specifications ordered are not marketable, they can apply for replacement within three months of the company’s delivery goods, the exchange quota is 2% of the annual delivery amount. In 2020 and 2021, the relevant returns and exchanges amounted to 144,300 yuan and 86,100 yuan respectively, accounting for 1.93% of the sales revenue of the relevant Sinopharm distributors in 2020. Affect the company's revenue recognition principles. According to the 2021 distribution agreement signed between the company and Sinopharm distributors, the above return and exchange clauses are no longer applicable. In principle, the company only allows returns and exchanges for product defects and quality problems caused by non-customer reasons.
COPAC SYSTEMS ApS purchased 210,400 yuan of closed sputum suction tubes from the company in April 2020. Later, due to differences of opinion between the two parties on product quality standards, , etc., after consultation, COPAC SYSTEMS ApS returned the previously purchased closed suction tube in January 2021. During the reporting period, there were no other transactions between the company and COPAC SYSTEMS ApS. The company adjusts the revenue and cost of the customer in 2020 according to adjustments after the balance sheet date . (Source: China Economic Net)
-
-
-
-
-
-
-
-
-
-